HPLC determination of a novel aroylhydrazone iron chelator (o-108) in rabbit plasma and its application to a pilot pharmacokinetic study

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 838, Issue 2, 2006, Pages 107-112

  Kovaříková, Petra ^a   Klimeš, Jiří ^a   Štěrba, Martin ^b   Popelová, Olga ^b   Geršl, Vladimír ^b   Poňka, Přemysl ^c  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

HPLC; Iron chelator; o 108; Pharmacokinetics; Pyridoxal 2 chlorobenzoyl hydrazone

Indexed keywords

CARBOXYLIC ACIDS; CHELATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IRON; PH EFFECTS; PHOSPHATES;

IRON CHELATOR; PHARMACOKINETICS; PYRIDOXAL 2-CHLOROBENZOYL HYDRAZONE;

ORGANOMETALLICS;

ACETONITRILE; BUFFER; EDETIC ACID; HYDRAZONE DERIVATIVE; IRON CHELATING AGENT; METHANOL; PHOSPHATE; PYRIDOXAL 2 CHLOROBENZOYL HYDRAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IRON CHELATION; MALE; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; RABBIT; TECHNIQUE; VALIDATION PROCESS;

ANIMALS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; HYDRAZONES; IRON CHELATING AGENTS; MALE; MOLECULAR STRUCTURE; PILOT PROJECTS; PYRIDOXAL; RABBITS; REPRODUCIBILITY OF RESULTS;

ORYCTOLAGUS CUNICULUS;

EID: 33745419399     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2006.04.020     Document Type: Article

References (17)

1. Kalinowski D.S., and Richardson D.R. Pharmacol. Rev. 57 (2005) 547
2. Tham T.F., Lejny-Toung R., Li W., Wang Y., Karimian K., and Spino M. Curr. Med. Chem. 10 (2003) 983
3. Simunek T., Boer C., Bouwman R.A., Vlasblom R., Versteilen A.M.A.M., Štěrba M., Geršl V., Hrdina R., Poňka P., de Lange J.J., Paulus W.J., and Musters R.J. J. Mol. Cell. Cardiol. 39 (2005) 345
4. Chaston T.B., Watts R.N., Yuan J., and Richardson D.R. Clin. Cancer Res. 10 (2004) 7365
5. Voest E.E., Vreugdenhil G., and Marx J.J.M. Ann. Intern. Med. 120 (1994) 490
6. Buss J.L., Torti F.M., and Torti S.V. Curr. Med. Chem. 10 (2003) 1021
7. Swain S.M., and Vici P. J. Cancer Res. Clin. Oncol. 130 (2004) 1
8. Cabantchik Z.I., Glickstein H., Golenser J., Loyevsky M., and Tsafack A. Acta Haematol. 95 (1996) 70
9. Richardson D.R. Ann. N.Y. Acad. Sci. 1012 (2004) 326
10. Buss J.L., Hermes-Lima M., and Poňka P. Adv. Exp. Med. Biol. 509 (2002) 205
11. Buss J.L., Arduini E., and Poňka P. Biochem. Pharmacol. 64 (2002) 1689
12. Buss J.L., Arduini E., Shepard K.C., and Poňka P. Biochem. Pharmacol. 65 (2003) 349
13. Štěrba M., Simunek T., Mazurova Y., Popelová O., Kaplanova J., Poňka P., and Geršl V. Hum. Exp. Toxicol. 24 (2005) 1
14. Link G., Poňka P., Konin A.M., Breuer W., Cabantchik Z.I., and Hersko C. Blood 101 (2003) 4172
15. Kovaříková P., Mokry M., Klimeš J., and Vavrova K. J. Sep. Sci. 27 (2004) 1503
16. Kovaříková P., Klimeš J., Štěrba M., Popelová O., Mokry M., Geršl V., and Poňka P. J. Sep. Sci. 28 (2005) 1300
17. CDER and CVM, Bioanalytical Method Validation, Guidance for Industry, May 2001 (http://www.fda.gov/cder/guidance/index.htm).